血糖控制不佳的2型糖尿病患者加用地特胰岛素或甘精胰岛素的临床研究被引量：25

A clinical study on adding detemir or glargine in not well-controlled type 2 diabetes

导出

摘要目的观察使用口服降糖药血糖控制不佳的2型糖尿病(T2DM)患者,分别加用地特胰岛素和甘精胰岛素治疗的有效性及安全性。方法 62例使用口服降糖药血糖控制不佳的T2DM患者,按1:1随机分为睡前加用地特胰岛素组(Det组)和甘精胰岛素组(Gla组),治疗3个月。结果治疗3个月后,两组HbA_1c、FPG、2hPG均较基线下降,但差异均无统计学意义(P>0.05)。两组低血糖发生率相同,均为6.5%。Det组体重增加明显低于Gla组(P<0.01)。两组胰岛素用量均为0.4～0.5U/kg。结论使用口服降糖药血糖控制不佳的T2DM患者,加用地特胰岛素或甘精胰岛素可以有效控制血糖且不增加低血糖风险。地特胰岛素在减少体重增加方面更有优势。 Objective To compare the efficacy and safety between basal insulin analogues detemir and glargine in type 2 diabetes. Methods Six-two diabetic patients were randomized to two groups of receiving insulin detemir （n=31） or glargine （n=31）once daily （at bedtime） for 3 months. Results HbAlc decreased from 8.6% to 7.0% （detemir） and 8.6% to 6.9% （glargine）. FPG decreased from 8.9 to 7.0 and 9.0 to 6.8 mmol/L, respectively. PPG decreased from 13.3 to 8.8 and 13.5 to 8.9mmol/L, respectively. There was no statistical difference between two groups（P〉0.05）. 6.5% patients in both detemir and glargine experienced hypoglycemia. Weight gain was lower in detemir than in glargine group （P〈0.01）. Dosage in both groups were around 0.4 - 0.5 U/kg. Conclusions Addition of insulin detemir or glargine to oral hypoglyeemic agents achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia. Treatment with detemir will achieve extra benefit in reducing weight gain.

作者郑骄阳石勇铨冯晓云刘志民

机构地区上海第二军医大学附属长征医院内分泌科

出处《中国糖尿病杂志》 CAS CSCD 北大核心 2010年第11期809-811,共3页 Chinese Journal of Diabetes

关键词糖尿病 2型地特胰岛素甘精胰岛素 Diabetes,type 2 Insulin detemir Insulin glargine

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献8

1Soran H,YounisN.Insulin dctemir:a new basal insulin analogue.Diabetes Obes Metab,2006,8:26-30.
2Kurtzhals P,Schaffer L,Sorens A.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.Diabetes,2000,49:999-1005.
3Rosenstock J,Davies M,Home PD,et al.A randomised,52-week,treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.Diabetologin,2008,51:408-416.
4Wiesli P,Krayenbuhl P,Uthoff H,et al.Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime:a prospective study in patients with type 2 diabetes.Diabetologia,2009,52:1816-1819.
5The Diabetes Control and Complications Research Group.Adverse events and their association with treatment regimens in the diabetes control and complications trial.Diabetes Care,1995,18:1415-1427.
6沈洁.地特胰岛素减少体重增加的可能机制与临床应用[J].中国糖尿病杂志,2010,18(3):238-240. 被引量：41
7Hennige AM,Sartorius T,Tschritter O,et al.Tissue selectivity of insulin detemir action in vivo.Diabetologia,2006,49:1274-1282.
8Hallschmid M,Jauch-Chara K,Korn O,et al.Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.Diabetes,2010,59:1101-1107.

二级参考文献30

1The Diabetes Control and Complications Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care, 1995,18 : 1415-1427.
2UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998,352: 837 -853.
3Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1997,82 : 4037-4043.
4DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care, 1988,11 : 567-573.
5Lin X, Taguchi A,Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and dia betes. J Clin Invest,2004,114:908-916.
6Brunner GA, Sendhofer G, Wutte A, et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes, 2000,108 : 100-105.
7Havelund S, Ribel U, Plum A, et al. The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes, 2004,53 : P462.
8Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insu lins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 2004,47 : 622-629.
9Raslovd K, Bogoev M, Raz I,et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract, 2004,66:193-201.
10Haak T, Tiengo A, Draeger E,et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab, 2005,7 : 56-64.